To explore the genetic basis of clonal hematopoiesis and its consequences, researchers analyzed genotyping data for more than 151,000 UK Biobank participants.
Near-term, the firm is focused on its cost structure and growing its top line with a view to becoming profitable, according to its interim CEO.
The collaborators have signed a two-year research and license option agreement to develop novel T-cell therapies for cancer using genome editing technology.
The firm is developing products suited for pharmaceutical development from biomarker discovery through companion diagnostics and disease monitoring.
The data included results from thousands of clinically tested samples showing frequent identification of clinically useful diagnostic and prognostic markers.
The company is focusing on hematological malignancies and looking to partner with pharmaceutical companies for companion diagnostics.
Despite an initial focus on cardiovascular disease, Miragen has moved programs in hematological cancer and fibrosis to the front of its pipeline.
The partners will map genomic variation and study its effects on patient outcomes to provide a resource for the prognosis of cancer patients and to help guide treatment for them.
The deal covers tests based on bone marrow and peripheral blood for hematologic cancers.
One of four new research centers, the collaborative network will look to push genomic and cell therapy technologies into clinical trials.
Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.
Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.
In Science this week: research regulation and reporting requirement reform, and more.
With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.